Tasigna advantage in treatment of newly diagnosed chronic myeloid leukemia: results of «Novartis research»
https://doi.org/10.17650/1818-8346-2009-0-4-61-64
References
1. Saglio G., Kim D.W., Issaragrisil S. et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: Results from the International Randomized Phase III ENESTnd Trial.
2. Tasigna (nilotinib) European Summary of Characteristics. Novartis AG. http://www.tasigna.com/en/tasigna-product-information.jsp#
3. Novartis data on file
4. NCCN Practice Guidelines in Oncology — v.1.2010. Chronic Myelogenous Leukemia.
5. National Cancer Institute. General Information About Chronic Myelogenous Leukemia (PDQ). http://www.cancer.gov/cancertopics/pdq/treatment/CML/patient/ Accessed March 2009.
6. American Cancer Society. Detailed Guide: CML. What are the key statistics about CML? Available at: http://www.cancer.org/docroot/CRI/content/CRI_2_4_1x_What_Are_the_Key_Statistics_About_Chronic_Myeloid_Leukemia_CML.asp?rnav=cri Accessed April 2009.
7. Central European Leukemia Study Group. About CML. [Cited 2009 Jan 13] Available from: http://www.cmlinfo.com/de/healthcareprofessionals/about-cml.html
8. Glivec® (imatinib) prescribing information. Novartis International AG; March 2009, Basel, Switzerland.
Review
For citations:
Tasigna advantage in treatment of newly diagnosed chronic myeloid leukemia: results of «Novartis research». Oncohematology. 2009;(4):61-64. (In Russ.) https://doi.org/10.17650/1818-8346-2009-0-4-61-64
Views:
139
Email this article 